These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
302 related articles for article (PubMed ID: 20083666)
1. Mechanisms of spatial and temporal development of autoimmune vitiligo in tyrosinase-specific TCR transgenic mice. Gregg RK; Nichols L; Chen Y; Lu B; Engelhard VH J Immunol; 2010 Feb; 184(4):1909-17. PubMed ID: 20083666 [TBL] [Abstract][Full Text] [Related]
2. GILT accelerates autoimmunity to the melanoma antigen tyrosinase-related protein 1. Rausch MP; Irvine KR; Antony PA; Restifo NP; Cresswell P; Hastings KT J Immunol; 2010 Sep; 185(5):2828-35. PubMed ID: 20668223 [TBL] [Abstract][Full Text] [Related]
3. Lymphatic endothelial cells induce tolerance via PD-L1 and lack of costimulation leading to high-level PD-1 expression on CD8 T cells. Tewalt EF; Cohen JN; Rouhani SJ; Guidi CJ; Qiao H; Fahl SP; Conaway MR; Bender TP; Tung KS; Vella AT; Adler AJ; Chen L; Engelhard VH Blood; 2012 Dec; 120(24):4772-82. PubMed ID: 22993390 [TBL] [Abstract][Full Text] [Related]
4. Transplantation of mouse HSCs genetically modified to express a CD4-restricted TCR results in long-term immunity that destroys tumors and initiates spontaneous autoimmunity. Ha SP; Klemen ND; Kinnebrew GH; Brandmaier AG; Marsh J; Hangoc G; Palmer DC; Restifo NP; Cornetta K; Broxmeyer HE; Touloukian CE J Clin Invest; 2010 Dec; 120(12):4273-88. PubMed ID: 21084750 [TBL] [Abstract][Full Text] [Related]
5. Autoimmune vitiligo does not require the ongoing priming of naive CD8 T cells for disease progression or associated protection against melanoma. Byrne KT; Zhang P; Steinberg SM; Turk MJ J Immunol; 2014 Feb; 192(4):1433-9. PubMed ID: 24403535 [TBL] [Abstract][Full Text] [Related]
6. Immune responses in a mouse model of vitiligo with spontaneous epidermal de- and repigmentation. Eby JM; Kang HK; Klarquist J; Chatterjee S; Mosenson JA; Nishimura MI; Garrett-Mayer E; Longley BJ; Engelhard VH; Mehrotra S; Le Poole IC Pigment Cell Melanoma Res; 2014 Nov; 27(6):1075-85. PubMed ID: 24935676 [TBL] [Abstract][Full Text] [Related]
7. Identification of Novel HLA-A*0201-Restricted CTL Epitopes in Chinese Vitiligo Patients. Cui T; Yi X; Guo S; Zhou F; Liu L; Li C; Li K; Gao T Sci Rep; 2016 Nov; 6():36360. PubMed ID: 27821860 [TBL] [Abstract][Full Text] [Related]
8. Engagement of NK receptor NKG2D, but not 2B4, results in self-reactive CD8+ T cells and autoimmune vitiligo. Zloza A; Lyons GE; Chlewicki LK; Kohlhapp FJ; O'Sullivan JA; Lacek AT; Moore TV; Jagoda MC; Kumar V; Guevara-Patiño JA Autoimmunity; 2011 Dec; 44(8):599-606. PubMed ID: 21913803 [TBL] [Abstract][Full Text] [Related]
9. Melanocyte-specific CD49a Yokoi K; Watanabe R; Kume M; Yamane S; Tanaka A; Fujimoto M; Tanemura A J Dermatol; 2023 May; 50(5):710-714. PubMed ID: 36514908 [TBL] [Abstract][Full Text] [Related]
10. Deletional self-tolerance to a melanocyte/melanoma antigen derived from tyrosinase is mediated by a radio-resistant cell in peripheral and mesenteric lymph nodes. Nichols LA; Chen Y; Colella TA; Bennett CL; Clausen BE; Engelhard VH J Immunol; 2007 Jul; 179(2):993-1003. PubMed ID: 17617591 [TBL] [Abstract][Full Text] [Related]
11. HLA-A2 restricted, melanocyte-specific CD8(+) T lymphocytes detected in vitiligo patients are related to disease activity and are predominantly directed against MelanA/MART1. Lang KS; Caroli CC; Muhm A; Wernet D; Moris A; Schittek B; Knauss-Scherwitz E; Stevanovic S; Rammensee HG; Garbe C J Invest Dermatol; 2001 Jun; 116(6):891-7. PubMed ID: 11407977 [TBL] [Abstract][Full Text] [Related]
12. Next-generation DNA re-sequencing identifies common variants of TYR and HLA-A that modulate the risk of generalized vitiligo via antigen presentation. Jin Y; Ferrara T; Gowan K; Holcomb C; Rastrou M; Erlich HA; Fain PR; Spritz RA J Invest Dermatol; 2012 Jun; 132(6):1730-3. PubMed ID: 22402439 [No Abstract] [Full Text] [Related]
13. Cytotoxic T lymphocyte reactivity to gp100, MelanA/MART-1, and tyrosinase, in HLA-A2-positive vitiligo patients. Mandelcorn-Monson RL; Shear NH; Yau E; Sambhara S; Barber BH; Spaner D; DeBenedette MA J Invest Dermatol; 2003 Sep; 121(3):550-6. PubMed ID: 12925214 [TBL] [Abstract][Full Text] [Related]
14. Inhibition of experimental autoimmune vitiligo by oral administration of mushroom tyrosinase. Zehtab T; Yazdanparast R; Rafieii S Cytobios; 2001; 105(408):27-34. PubMed ID: 11368265 [TBL] [Abstract][Full Text] [Related]
15. Specific cytotoxic T lymphocyte responses against Melan-A/MART1, tyrosinase and gp100 in vitiligo by the use of major histocompatibility complex/peptide tetramers: the role of cellular immunity in the etiopathogenesis of vitiligo. Palermo B; Campanelli R; Garbelli S; Mantovani S; Lantelme E; Brazzelli V; Ardigó M; Borroni G; Martinetti M; Badulli C; Necker A; Giachino C J Invest Dermatol; 2001 Aug; 117(2):326-32. PubMed ID: 11511311 [TBL] [Abstract][Full Text] [Related]
16. A mouse model of vitiligo with focused epidermal depigmentation requires IFN-γ for autoreactive CD8⁺ T-cell accumulation in the skin. Harris JE; Harris TH; Weninger W; Wherry EJ; Hunter CA; Turka LA J Invest Dermatol; 2012 Jul; 132(7):1869-76. PubMed ID: 22297636 [TBL] [Abstract][Full Text] [Related]
17. A quantitative increase in regulatory T cells controls development of vitiligo. Chatterjee S; Eby JM; Al-Khami AA; Soloshchenko M; Kang HK; Kaur N; Naga OS; Murali A; Nishimura MI; Caroline Le Poole I; Mehrotra S J Invest Dermatol; 2014 May; 134(5):1285-1294. PubMed ID: 24366614 [TBL] [Abstract][Full Text] [Related]